339 related articles for article (PubMed ID: 22160862)
1. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.
Terry T; Raravikar K; Chokrungvaranon N; Reaven PD
Curr Cardiol Rep; 2012 Feb; 14(1):79-88. PubMed ID: 22160862
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
Meier M; Hummel M
Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
[TBL] [Abstract][Full Text] [Related]
3. Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia.
Shogbon AO; Levy SB
Am J Health Syst Pharm; 2010 May; 67(10):798-805. PubMed ID: 20479101
[TBL] [Abstract][Full Text] [Related]
4. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis.
Ma J; Yang W; Fang N; Zhu W; Wei M
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):596-603. PubMed ID: 19819121
[TBL] [Abstract][Full Text] [Related]
5. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
Weiss IA; Valiquette G; Schwarcz MD
Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
[TBL] [Abstract][Full Text] [Related]
6. Glycemic control and cardiovascular disease: what's a doctor to do?
Kishore P; Kim SH; Crandall JP
Curr Diab Rep; 2012 Jun; 12(3):255-64. PubMed ID: 22467273
[TBL] [Abstract][Full Text] [Related]
7. [Glycemic control and cardiovascular benefit: What do we know today?].
Hanefeld M; Schönauer M; Forst T
Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
[TBL] [Abstract][Full Text] [Related]
8. An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
Konig M; Lamos EM; Stein SA; Davis SN
Curr Diabetes Rev; 2013 Sep; 9(5):371-81. PubMed ID: 23865412
[TBL] [Abstract][Full Text] [Related]
9. Glucose control in diabetes: which target level to aim for?
Laakso M; Cederberg H
J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
[TBL] [Abstract][Full Text] [Related]
10. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
Kitasato L; Tojo T; Hatakeyama Y; Kameda R; Hashikata T; Yamaoka-Tojo M
Cardiovasc Diabetol; 2012 Jun; 11():79. PubMed ID: 22748110
[TBL] [Abstract][Full Text] [Related]
11. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
Aryangat AV; Gerich JE
Vasc Health Risk Manag; 2010 Mar; 6():145-55. PubMed ID: 20448799
[TBL] [Abstract][Full Text] [Related]
12. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino F; Home PD; Tuomilehto J
Diabetes Care; 2016 Aug; 39 Suppl 2():S187-95. PubMed ID: 27440832
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and cardiovascular disease: the role of glycemic control.
Cheng AY; Leiter LA
Curr Diab Rep; 2009 Feb; 9(1):65-72. PubMed ID: 19192427
[TBL] [Abstract][Full Text] [Related]
14. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal.
Scheen AJ; Charbonnel B
Diabetes Metab; 2014 Jun; 40(3):176-85. PubMed ID: 24792220
[TBL] [Abstract][Full Text] [Related]
15. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
17. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.
Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT;
Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
[TBL] [Abstract][Full Text] [Related]
19. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).
Kosiborod M; Gomes MB; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Watada H; Shimomura I; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Khunti K;
Cardiovasc Diabetol; 2018 Nov; 17(1):150. PubMed ID: 30486889
[TBL] [Abstract][Full Text] [Related]
20. [Hypoglycemia and cardiovascular risk].
Avogaro A
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
